Publication: Familias isoflavona reductasa y Ole e 1-like: relevancia de alérgenos minoritarios en especies vegetales de climas mediterráneos
Loading...
Files
Official URL
Full text at PDC
Publication Date
2016-04-05
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La hipersensibilidad de tipo I, conocida como alergia atópica, es una respuesta inmunológica alterada y mediada por anticuerpos IgE (inmunoglobulina E), dirigida frente a determinados antígenos denominados alérgenos, la gran mayoría de los cuales son moléculas inocuas para el ser humano en condiciones normales. Esta hiperreactividad o reacción excesiva del sistema inmune resulta perjudicial para el organismo y su incidencia ha aumentado de forma notable en los últimos años, estimándose que afecta aproximadamente al 35% de la población europea y al 25% de la población de los países desarrollados. Actualmente, tanto el diagnóstico y la inmunoterapia de la alergia se llevan a cabo mediante la exposición del paciente a los extractos de la fuente alergénica. El diagnóstico de la alergia de tipo I se basa en la combinación de criterios sintomatológicos clínicos y características fisiopatológicas, determinadas por pruebas in vivo, como pruebas cutáneas (SPT), test de provocación nasal u oral con el extracto alergénico o pruebas in vitro, como los ensayos mediante radioalergoabsorción (RAST) o inmunocaptura (InmunoCAP/ADVIA centauro). En general, el SPT se complementa con ensayos in vitro que permiten cuantificar los niveles de IgE total y específica presente en el suero del paciente: RAST e InmunoCAP/ADVIA centauro. Estos ensayos, al contrario que el SPT, no se ven afectados por el empleo de fármacos como los antihistamínicos...
Type I hypersensitivity, known as atopic allergy, is an altered immune response, mediated by IgE antibodies (immunoglobulin E) directed against certain antigens called allergens, which most of them are, in standard conditions, molecules harmless to humans. This hyperreactivity or overreaction of the immune system is harmful to the body and its incidence has increased significantly in recent years, estimated to affect about 35% of the European population and 25% of the population of developed countries. Currently, both the diagnosis and immunotherapy of allergy are conducted by exposing the patient to extracts of the allergen source. The diagnosis of Type I allergy is based on the combination of clinical and symptomatological criteria determined by in vivo tests such as skin tests (SPT), nasal or oral test provocation with allergen extract or in vitro tests such as tests using radioallergosorbent (RAST) or immunocapture (ImmunoCAP / ADVIA centaur) assays. In general, the SPT is complemented by in vitro assays to quantify levels of total and specific IgE present in the patient's serum: ImmunoCAP RAST and / ADVIA Centaur. These tests, unlike the SPT, are not affected by the use of drugs such as antihistamines. However, the use of allergen extracts for diagnosing presents some problems, such as variability in the composition of the extracts, the presence of labile allergens in the natural source which is not present in the extract or who are underrepresented compared to the allergenic source. Thus, identification and isolation of natural allergens, production of recombinant allergens and characterization of their properties, offers new perspectives from a clinical point of view to improve diagnostic protocols and future applications for disease treatment. Currently, the use of recombinant molecules for this purpose is not allowed in Spain...
Type I hypersensitivity, known as atopic allergy, is an altered immune response, mediated by IgE antibodies (immunoglobulin E) directed against certain antigens called allergens, which most of them are, in standard conditions, molecules harmless to humans. This hyperreactivity or overreaction of the immune system is harmful to the body and its incidence has increased significantly in recent years, estimated to affect about 35% of the European population and 25% of the population of developed countries. Currently, both the diagnosis and immunotherapy of allergy are conducted by exposing the patient to extracts of the allergen source. The diagnosis of Type I allergy is based on the combination of clinical and symptomatological criteria determined by in vivo tests such as skin tests (SPT), nasal or oral test provocation with allergen extract or in vitro tests such as tests using radioallergosorbent (RAST) or immunocapture (ImmunoCAP / ADVIA centaur) assays. In general, the SPT is complemented by in vitro assays to quantify levels of total and specific IgE present in the patient's serum: ImmunoCAP RAST and / ADVIA Centaur. These tests, unlike the SPT, are not affected by the use of drugs such as antihistamines. However, the use of allergen extracts for diagnosing presents some problems, such as variability in the composition of the extracts, the presence of labile allergens in the natural source which is not present in the extract or who are underrepresented compared to the allergenic source. Thus, identification and isolation of natural allergens, production of recombinant allergens and characterization of their properties, offers new perspectives from a clinical point of view to improve diagnostic protocols and future applications for disease treatment. Currently, the use of recombinant molecules for this purpose is not allowed in Spain...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Ciencias Químicas, Departamento de Bioquímica y Biología Molecular I, leída el 01-12-2015